Senthil Vel Sundaram
Net Worth

Last updated:

What is Senthil Vel Sundaram net worth?

The estimated net worth of Mr. Senthil Vel Sundaram is at least $1,806,960 as of 31 May 2023. He owns shares worth $61,650 as insider and has received compensation worth at least $1,745,310 in Terns Pharmaceuticals, Inc..

What is the salary of Senthil Vel Sundaram?

Mr. Senthil Vel Sundaram salary is $581,770 per year as Chief Executive Officer & Director in Terns Pharmaceuticals, Inc..

How old is Senthil Vel Sundaram?

Mr. Senthil Vel Sundaram is 47 years old, born in 1978.

What stocks does Senthil Vel Sundaram currently own?

As insider, Mr. Senthil Vel Sundaram owns shares in one company:

Company Title Shares Price per share Total value
Terns Pharmaceuticals, Inc. (TERN) Chief Executive Officer & Director 9,770 $6.31 $61,650

What does Terns Pharmaceuticals, Inc. do?

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

Senthil Vel Sundaram insider trading

Terns Pharmaceuticals, Inc.

Transaction Date Security Shares Price per share Total value Source
Purchase
Common Stock 2,111 $1.41 $2,977
Purchase
Common Stock 7,656 $1.47 $11,254

Terns Pharmaceuticals key executives

Terns Pharmaceuticals, Inc. executives and other stock owners filed with the SEC: